These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36967847)

  • 1. Intraosseous transplant of dystrophin expressing chimeric (DEC) cells improves skeletal muscle function in
    Malik M; Siemionow M; Cwykiel J; Heydemann A; Garcia-Martinez J; Siemionow K; Szilagyi E
    Postepy Kardiol Interwencyjnej; 2022 Dec; 18(4):399-406. PubMed ID: 36967847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transplantation of Dystrophin Expressing Chimeric Human Cells of Myoblast/Mesenchymal Stem Cell Origin Improves Function in Duchenne Muscular Dystrophy Model.
    Siemionow M; Szilagyi E; Cwykiel J; Domaszewska-Szostek A; Heydemann A; Garcia-Martinez J; Siemionow K
    Stem Cells Dev; 2021 Feb; 30(4):190-202. PubMed ID: 33349121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac Protection after Systemic Transplant of Dystrophin Expressing Chimeric (DEC) Cells to the mdx Mouse Model of Duchenne Muscular Dystrophy.
    Siemionow M; Malik M; Langa P; Cwykiel J; Brodowska S; Heydemann A
    Stem Cell Rev Rep; 2019 Dec; 15(6):827-841. PubMed ID: 31612351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
    Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
    Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy.
    Siemionow M; Cwykiel J; Heydemann A; Garcia J; Marchese E; Siemionow K; Szilagyi E
    Stem Cell Rev Rep; 2018 Jun; 14(3):370-384. PubMed ID: 29546607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy.
    Siemionow M; Cwykiel J; Heydemann A; Garcia-Martinez J; Siemionow K; Szilagyi E
    Stem Cell Rev Rep; 2018 Apr; 14(2):189-199. PubMed ID: 29305755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Biodistribution and Safety of Human Dystrophin Expressing Chimeric Cell Therapy After Systemic-Intraosseous Administration to Duchenne Muscular Dystrophy Model.
    Siemionow M; Brodowska S; Langa P; Zalants K; Kozlowska K; Grau-Kazmierczak W; Heydemann A
    Arch Immunol Ther Exp (Warsz); 2022 Aug; 70(1):20. PubMed ID: 35978142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amelioration of Morphological Pathology in Cardiac, Respiratory, and Skeletal Muscles Following Intraosseous Administration of Human Dystrophin Expressing Chimeric (DEC) Cells in Duchenne Muscular Dystrophy Model.
    Siemionow M; Budzynska K; Zalants K; Langa P; Brodowska S; Siemionow K; Heydemann A
    Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle's function in Duchenne muscular dystrophy.
    Siemionow M; Langa P; Harasymczuk M; Cwykiel J; Sielewicz M; Smieszek J; Heydemann A
    Stem Cells Transl Med; 2021 Oct; 10(10):1406-1418. PubMed ID: 34291884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric Cell Therapy Transfers Healthy Donor Mitochondria in Duchenne Muscular Dystrophy.
    Siemionow M; Bocian K; Bozyk KT; Ziemiecka A; Siemionow K
    Stem Cell Rev Rep; 2024 Oct; 20(7):1819-1829. PubMed ID: 39017908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up.
    Heydemann A; Bieganski G; Wachowiak J; Czarnota J; Niezgoda A; Siemionow K; Ziemiecka A; Sikorska MH; Bozyk K; Tullius SG; Siemionow M
    Stem Cell Rev Rep; 2023 Jul; 19(5):1340-1359. PubMed ID: 37000376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of Chimeric Cell Therapy in Duchenne Muscular Dystrophy.
    Siemionow M; Ziemiecka A; Bożyk K; Siemionow K
    Biomedicines; 2024 Sep; 12(9):. PubMed ID: 39335509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of ultrasonography for non-invasive assessment of diaphragm function in muscular dystrophy.
    Whitehead NP; Bible KL; Kim MJ; Odom GL; Adams ME; Froehner SC
    J Physiol; 2016 Dec; 594(24):7215-7227. PubMed ID: 27570057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric Cell Therapies as a Novel Approach for Duchenne Muscular Dystrophy (DMD) and Muscle Regeneration.
    Budzynska K; Siemionow M; Stawarz K; Chambily L; Siemionow K
    Biomolecules; 2024 May; 14(5):. PubMed ID: 38785982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoration of pharyngeal dilator muscle force in dystrophin-deficient (mdx) mice following co-treatment with neutralizing interleukin-6 receptor antibodies and urocortin 2.
    Burns DP; Rowland J; Canavan L; Murphy KH; Brannock M; O'Malley D; O'Halloran KD; Edge D
    Exp Physiol; 2017 Sep; 102(9):1177-1193. PubMed ID: 28665499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Live-imaging of revertant and therapeutically restored dystrophin in the Dmd
    Petkova MV; Stantzou A; Morin A; Petrova O; Morales-Gonzalez S; Seifert F; Bellec-Dyevre J; Manoliu T; Goyenvalle A; Garcia L; Richard I; Laplace-Builhé C; Schuelke M; Amthor H
    Neuropathol Appl Neurobiol; 2020 Oct; 46(6):602-614. PubMed ID: 32573804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the
    Potter RA; Griffin DA; Heller KN; Peterson EL; Clark EK; Mendell JR; Rodino-Klapac LR
    Hum Gene Ther; 2021 Apr; 32(7-8):375-389. PubMed ID: 33397205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isometric resistance training increases strength and alters histopathology of dystrophin-deficient mouse skeletal muscle.
    Lindsay A; Larson AA; Verma M; Ervasti JM; Lowe DA
    J Appl Physiol (1985); 2019 Feb; 126(2):363-375. PubMed ID: 30571283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photobiomodulation therapy protects skeletal muscle and improves muscular function of mdx mice in a dose-dependent manner through modulation of dystrophin.
    Albuquerque-Pontes GM; Casalechi HL; Tomazoni SS; Serra AJ; Ferreira CSB; Brito RBO; de Melo BL; Vanin AA; Monteiro KKDS; Dellê H; Frigo L; Marcos RL; de Carvalho PTC; Leal-Junior ECP
    Lasers Med Sci; 2018 May; 33(4):755-764. PubMed ID: 29209866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy.
    Chesshyre M; Ridout D; Hashimoto Y; Ookubo Y; Torelli S; Maresh K; Ricotti V; Abbott L; Gupta VA; Main M; Ferrari G; Kowala A; Lin YY; Tedesco FS; Scoto M; Baranello G; Manzur A; Aoki Y; Muntoni F
    J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1360-1372. PubMed ID: 35083887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.